Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is a biopharmaceutical company with a single segment focused on developing and commercializing therapeutic products for life-threatening diseases. The company's lead product, DefenCath, has shown positive results in reducing catheter-related bloodstream infections in hemodialysis patients. Cormedix also has potential for future growth through label expansion opportunities and its recent acquisition of Melinta assets. Key financial metrics to note are a forecasted ~$190M in peak non-risk adjusted sales for DefenCath in its current indication in 2030E and ~$220M in peak non-risk adjusted sales for Rezzayo in an expanded indication in 2034E. With strong data backing its products and multiple potential growth drivers, we believe Cormedix has a positive outlook for future success and revenue growth.

Bears say

Cormedix is facing several fundamental challenges, including a potential lack of differentiation in the safety profile of its lead product, DefenCath, compared to other prophylaxis options, as well as potential barriers to obtaining a broader label expansion. Additionally, the company's recent acquisition of Melinta could also create risks and challenges in terms of regulatory, commercial, and pricing pressures. Overall, these factors could impact the company's growth potential and generate uncertainty around its valuation, warranting a cautious outlook on the stock.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.